- Home
- NOTV vs HLVX Comparison
NOTV vs HLVX Comparison
Compare NOTV & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- HLVX
- Stock Information
- Founded
- NOTV 1974
- HLVX 2020
- Country
- NOTV United States
- HLVX United States
- Employees
- NOTV N/A
- HLVX N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- NOTV Health Care
- HLVX Health Care
- Exchange
- NOTV Nasdaq
- HLVX Nasdaq
- Market Cap
- NOTV 95.2M
- HLVX 87.6M
- IPO Year
- NOTV 1997
- HLVX 2022
- Fundamental
- Price
- NOTV $3.95
- HLVX $1.86
- Analyst Decision
- NOTV Strong Buy
- HLVX Hold
- Analyst Count
- NOTV 3
- HLVX 5
- Target Price
- NOTV $5.92
- HLVX $2.33
- AVG Volume (30 Days)
- NOTV 1.4M
- HLVX 252.8K
- Earning Date
- NOTV 02-05-2025
- HLVX 11-07-2024
- Dividend Yield
- NOTV N/A
- HLVX N/A
- EPS Growth
- NOTV N/A
- HLVX N/A
- EPS
- NOTV N/A
- HLVX N/A
- Revenue
- NOTV $490,739,000.00
- HLVX N/A
- Revenue This Year
- NOTV $7.14
- HLVX N/A
- Revenue Next Year
- NOTV $5.73
- HLVX N/A
- P/E Ratio
- NOTV N/A
- HLVX N/A
- Revenue Growth
- NOTV N/A
- HLVX N/A
- 52 Week Low
- NOTV $1.23
- HLVX $1.55
- 52 Week High
- NOTV $11.42
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- NOTV 49.75
- HLVX 43.91
- Support Level
- NOTV $4.63
- HLVX $1.95
- Resistance Level
- NOTV $6.48
- HLVX $2.13
- Average True Range (ATR)
- NOTV 0.76
- HLVX 0.08
- MACD
- NOTV 0.02
- HLVX -0.01
- Stochastic Oscillator
- NOTV 17.05
- HLVX 0.00
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery and development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, it supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through the RMS segment, it offers access to a wide range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas. It earns maximum revenue from RMS Segment.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.